Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 82

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 82
---
undedWarrant may be transferred at the option of the holder upon surrender of the February 2025 Pre -FundedWarrant to us together with the appropriate instruments of transfer. Fractional Shares:No fractional shares of Common Stock will be issued upon the exercise of the February 2025 Pre -FundedWarrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price. Trading Market:There is no trading market available for the February 2025 Pre -FundedWarrants on any securities exchange or nationally recognized trading system. Fundamental Transactions:If a “Fundamental Transaction” occurs while the February 2025 Pre -FundedWarrants are outstanding (which includes, but is not limited to, merger transactions or a sale of substantially all of the company’s assets), then if holders of the Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction (as defined in the February 2025 Pre -FundedWarrant), then the holder will be given the same choice as to the consideration it receives upon any exercise of either the February 2025 Pre -FundedWarrants following such Fundamental Transaction. 44 Right as a Stockholder:Except as otherwise provided in the February 2025 Pre -FundedWarrants or by virtue of such holder’s ownership of shares of our Common Stock, the holders of the February 2025 Pre -FundedWarrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, until they exercise their February 2025 Pre -FundedWarrants. February 2025 Common Warrants The following summary of certain terms and provisions of the February 2025 Common Warrants that are is not complete and is subject to, and qualified in its entirety by, the provisions of the February 2025 Common Warrant, the form of which is filed as Exhibit 4.7 to the registration statement filed with the SEC on February 5, 2025. Prospective investors should carefully review the terms and provisions of the form of February 2025 Common Warrant for a complete description of the terms and conditions of the February 2025 Common Warrants. We issued and sold 127,551 February 2025 Common Warrants to purchase an aggregate of 127,551shares of our